Table 3.
Association of MMP12 polymorphisms with clinical stage and ER/PR status in breast cancer patients
| MMP12 genotype | ||||
| TNM stage No. (%) | ||||
| Analyzed according to stage of cancer | 0, I, or II | III or IV | P | |
| A-82G | ||||
| AA | 876 (95.1) | 113 (93.4) | 0.42 | |
| AG/GG | 45 (4.9) | 8 (6.6) | ||
| A1082G (Asn357Ser) | ||||
| AA | 606 (80.5) | 81 (79.4) | 0.80 | |
| AG/GG | 147 (19.5) | 21 (20.6) | ||
| Presence of any minor genotypesa | ||||
| No | 563 (75.6) | 74 (74.0) | 0.73 | |
| Yes | 182 (24.4) | 26 (26.0) | ||
| Analyzed according to ER/PR status | ER+/PR+ No. (%) | ER-/PR- No. (%) | ER+/PR- or ER-/PR+ No. (%) | |
| A-82G | ||||
| AA | 401 (97.1) | 188 (93.5) | 144 (95.4) | 0.11 |
| AG/GG | 12 (2.9) | 13 (6.5) | 7 (4.6) | |
| A1082G (Asn357Ser) | ||||
| AA | 251 (77.0) | 145 (84.8) | 102 (83.6) | 0.07 |
| AG/GG | 75 (23.0) | 26 (15.2) | 20 (16.4) | |
| Presence of any minor genotypesa | ||||
| No | 238 (74.1) | 133 (78.2) | 96 (79.3) | 0.41 |
| Yes | 83 (25.9) | 37 (21.8) | 25 (20.7) | |
aAG/GG genotypes for A-82G and AG/GG genotype for A1082G polymorphisms. ER, estrogen receptor; PR, progesterone receptor; TNM, tumor, node, metastasis.